Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hyman

Showing results (21-30 of 174) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2016
Measuring Toxicity in Phase I Clinical Trials--LetterDavid M Hyman, Anne Eaton, S Percy Ivy, et al.
Gynecologic Oncology Reports|January 22, 2016
Primary debulking surgery for metastatic cervical adenocarcinoma: A case reportSara M Davenport, Rudy S Suidan, James Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2018
Learning All That We Can From MyPathwayJessica J Tao, Alison M Schram, James J Harding, et al.
Clinical Nuclear Medicine|September 6, 2017
89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast CancerGary A Ulaner, David M Hyman, Serge K Lyashchenko, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 29, 2012
Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experienceRachel Nicole Grisham, Christina Adaniel, David M Hyman, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2014
BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiationOlga L Bohn, Katharine Hsu, David M Hyman, et al.
Ocular Oncology and Pathology|June 9, 2020
MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR VariantsJasmine H Francis, Eli L Diamond, Ping Chi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2012
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trialsAlexia Iasonos, Mrinal Gounder, David R Spriggs, et al.
JAMA Oncology|March 1, 2019
Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access ProgramNoah Z Feit, Debra A Goldman, Evan Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Reply to M. Voskoboynik et alDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Pageof 18

Showing results (21-30 of 174) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2016
Measuring Toxicity in Phase I Clinical Trials--LetterDavid M Hyman, Anne Eaton, S Percy Ivy, et al.
Gynecologic Oncology Reports|January 22, 2016
Primary debulking surgery for metastatic cervical adenocarcinoma: A case reportSara M Davenport, Rudy S Suidan, James Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2018
Learning All That We Can From MyPathwayJessica J Tao, Alison M Schram, James J Harding, et al.
Clinical Nuclear Medicine|September 6, 2017
89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast CancerGary A Ulaner, David M Hyman, Serge K Lyashchenko, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 29, 2012
Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experienceRachel Nicole Grisham, Christina Adaniel, David M Hyman, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 22, 2014
BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiationOlga L Bohn, Katharine Hsu, David M Hyman, et al.
Ocular Oncology and Pathology|June 9, 2020
MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR VariantsJasmine H Francis, Eli L Diamond, Ping Chi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2012
The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trialsAlexia Iasonos, Mrinal Gounder, David R Spriggs, et al.
JAMA Oncology|March 1, 2019
Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access ProgramNoah Z Feit, Debra A Goldman, Evan Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
Reply to M. Voskoboynik et alDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Pageof 18